Response to: lower-dose valganciclovir for prevention of cytomegalovirus after solid organ transplant: an important tradeoff.
Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
D R
DR
Stevens
Department of Medicine, Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
D
D
Sawinski
Department of Medicine, Infectious Disease Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
E
E
Blumberg
Department of Medicine, Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
R D
RD
Bloom
Department of Pharmacy Services, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.|Department of Medicine, Renal Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J
J
Trofe-Clark
D064591:Allografts / Q000821:virology*; D000998:Antiviral Agents / Q000008:administration & dosage*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000031:analogs & derivatives*; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation; D008297:Male
D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D015774:Ganciclovir
CMV; infection; prophylaxis; valganciclovir